Introduction
Although a steady decline of prostate cancer-related death in the past decade and numerous advances in early diagnosis and monitoring, advanced disease at the castration-resistant stage is still a big challenge for the community (1) . While a few chemical compounds were approved for clinical use, currently castration-resistant prostate cancers (CRPC) are virtually not curable due to lack of substantial response to most of therapeutic agents that are clinically available (2) .
Therefore, development of effective therapies is an urgent need for this patient population.
The novel compound Alternol was isolated from fermenting products by microorganism named as Alternaria alternata var. monosporus, which was obtained from the bark of yew tree in Kunming, China (3) (4) (5) . This source is similar as the current anti-cancer drug Paclitaxel (6) , which has been effectively used for lung, breast and gastric cancers, and its derivative Docetaxel has been approved for use in prostate cancers (7) . It has been shown that Alternol induced cell cycle arrest, interrupted epithelial-to-mesenchymal transition and apoptotic cell death in human cancer cell lines (3-5, 8, 9) . A recent publication showed that Alternol preferentially kills prostate cancer cells over non-malignant prostatic epithelial cells, indicating a potential benefit for prostate cancer patients (10) . 
Reactive oxygen species (ROS) is
, which contain one or more unpaired electron(s); and non-radical ROS, such as hydrogen peroxide (H 2 O 2 ) or singlet oxygen, which do not contain unpaired electrons but are highly reactive and can give rise to radical forms of ROS (11) . It has become increasingly evident that certain anticancer agents induce intracellular oxidative stress that is either the primary mechanism of cell death or is a secondary indirect effect that may lead to cell death (11, 12) . Furthermore, cancer cells are more vulnerable to oxidative stress caused by ROS-inducing agents. Due to differential redox states between normal and cancer cells, the therapeutic strategies would be reconsidered to selectively utilize these ROS-inducing agents for cancer therapy (11) .
Bax, the Bcl-2-associated X protein, is a cardinal pro-apoptotic member of BCL-2 family proteins, which regulates the critical balance between cell survival and death (13) . It has been demonstrated that Bax transforms into a lethal mitochondrial oligomer in response to cellular stress and becomes activated to cause mitochondrial damage, a key step for the intrinsic pathway to apoptosis (14) (15) (16) . The mechanisms that push Bax to mitochondria are not entirely clear but previous reports have shown that oxidative stress-induced dimerization promoted Bax translocation to mitochondria and that ROS acts upstream of calpain-mediated mitochondrial Bax cleavage (17) (18) (19) (20) .
In attempt to develop novel chemotherapy for CRPCs, we evaluated the anti-cancer effect of Alternol on multiple prostate cancer cell lines in comparison to non-malignant prostate-derived epithelial cells. In this report we demonstrated that Alternol induced massive cell killing in prostate cancer cells but less toxic to non-malignant prostate epithelial cells through an oxidative stress-dependent mechanism. We also confirmed that the pro-apoptotic protein Bax was activated in response to oxidative stress, which is critical in Alternol-induced apoptotic cell death.
Animal experiments in nude mice indicated that Alternol treatment largely suppressed xenografts tumor growth in vivo. These data suggest that Alternol might be developed as a novel therapeutic agent for CRPC patients. 
Materials and Methods
Cell culture, antibodies, and reagents RWPE-1, LNCaP, DU145, PC-3 and 22RV1 cells were purchased from ATCC (Manassas, VA) in February 2002 and maintained in a humidified atmosphere of 5% CO 2 , RPMI 1640 supplemented with 10% fetal bovine serum (FBS) and antibiotics except that RWPE-1 cells were maintained in Keratinocyte-SFM media (Invitrogen, Carlsbad, CA). LAPC-4 was obtained from UCLA and C4-2 was purchased from UroCor (Oklahoma City, OK) in May 2002 as described in our previous publications (21, 22) . BPH1 cell line was kindly provided by Dr Long-cheng Li (Department of Urololgy, University of California at San Francisco) in August 2011. These cell lines were authenticated using Promega PowerPlex® technology and carried out at Genetica® DNA Laboratories (Burlington, NC) in January 2014. Alternol (99.9% purity) was a kind gift from Strand Biotech Co (Shantou, China) and its structural scheme is shown in Fig 1A . 
Cytotoxicity, flow cytometry and mitochondrial membrane potential assays
Cells were seeded at 3 × 10 4 cells/well in 12-well plates (trypan-blue assay) or in 6-well plate (flow cytometry assay). The next day, cells were treated with the solvent or Alternol as described in the figure legend. Cell viability was assessed with a trypan blue exclusion assay (22) .
Apoptotic cell death was evaluated with a flow cytometry-based Annexin V binding and PI staining assay, as described in our previous publication (22) .
Mitochondrial Membrane Potential assay was done as previously described (22) . Briefly, PC-3 cells were treated with the solvent (DMSO) or Alternol in the presence or absence of the antioxidants as indicated in the figures. Then PC-3 cells were incubated with JC-1 (0.3 μg/ml) for 15 min at 37°C. Thereafter, cells were analyzed and microscopic images were taken under a fluorescent microscope (Olympus, Japan), as described in our previous publications (22, 24) .
DNA fragmentation and Caspase-9 activity assays
Cells were treated as indicated in the figures. Total genomic DNA was extracted using the DNA ladder detection kit by following the manufacturer's instructions. DNA ladders were analyzed on 1% agarose gel electrophoresis. For caspases-9 assay, PC-3 cells were treated with the solvent or Alternol as indicated in the figures. Cells were rinsed with ice-cold PBS and lysed on ice in cell lysis buffer from the Caspase-9 colorimetric activity assay kit. Caspase-9 activity was measured by following the manufacturer's manual and presented as a relative value compared to the solvent control that was set as a value of 1.0.
Western blot assay
After treatment, cells were rinsed with ice-cold PBS and lysed on ice in RIPA buffer (Cell Signal, MA). Equal amount of proteins from each lysates was loaded onto SDS-PAGE gels, electrophoresed, and transferred onto PVDF membrane. Following electrotransfer, the membrane was blocked for 2 h in 5% nonfat dried milk; and then incubated with primary antibody overnight at 4°C. Visualization of the protein signal was achieved with horseradish peroxidase conjugated secondary antibody and enhanced chemiluminescence procedures according to the manufacturer's recommendation (Santa Cruz Biotech, Santa Cruz, CA).
Measurement of intracellular reactive oxygen species
The level of intracellular ROS generation was assessed with the total ROS detection kit (Enzo Life) by following the manufacturer's instructions. Cells were seeded in a 24-well culture plate. 
Mouse xenografts model and Alternol treatment
Athymic NCr-nu/nu male mice (NCI-Frederick, Fort Detrick, VA, USA) were maintained in accordance with the Institutional Animal Care and Use Committee (IACUC) procedures and guidelines. Xenograft tumors were generated as described in our recent publications (24, 25) . ]/2), as described previously (24) .
Animal body weight and the wet weights of dissected xenograft tumors were recorded at the end of drug treatment.
Immunohistochemical staining and in situ TUNEL assay
Immunohistochemical staining assay was done as previously described (24) (25) (26) . Xenograft specimens were fixed in 4% paraformaldehyde and paraffin-embedded. Sections were deparaffinized and rehydrated, followed by antigen retrieval and endogenous peroxidase blocking. Multiple dilutions of the primary IHC-specific antibody for cleaved caspases-3 (Catalog #9661, Cell Signal, Danvers, MA) were utilized to achieve optimal immunosignals. A negative control was set up for each case by omitting the primary antibody. Immunosignals were detected with DAKO LSAB+ System by following the manufacturer's manual. Apoptosis index in tissue sections was determined by in situ TUNEL analysis with the ApoAlert ΤΜ DNA fragmentation assay kit (Clontech, Mountain View, CA), as described previously (24) .
Statistical analysis
Images of western blots, Total ROS Detection, JC-1 staining, flow cytometry analysis, DNA fragmentation assay, in situ TUNEL assay and IHC microscopic images were from representative experiments. The mean and standard error of the mean (SEM) are shown for all of the quantitative data. The significance of the differences between treatment and control was analyzed by ANOVA or Student t-test as indicated in the figure legends using SPSS software (SPSS, Chicago, IL). Alternol's IC 50 value was calculated with the Four-Parameter Logistic Function using the SPSS software.
Results

Alternol treatment induces cell death in prostate cancer cells but not in normal prostate cells.
It was recently reported that Alternol induced growth inhibition and apoptosis in human cancer cells, including prostate cancer cells (4, 10 
quantified using trypan-blue exclusion assay. We first conducted a dose-response test in three representative prostate cancer cell lines, androgen responsive LNCaP, castration-resistant C4-2 and androgen receptor (AR)-negative PC-3. As shown in Fig 1B, a clear (Fig 1C) . These data indicate that Alternol has a preference in killing prostate cancer cells over non-malignant prostate epithelial cells, which is supported by a recent report (10) . The case for cell death resistance in prostate cancer DU145 cells might be due to defect of cell death pathway that will be explained later.
Alternol-induced cell death is mainly an apoptotic response.
To determine if Alternol-induced cell death is an apoptotic response as reported in gastric cancer cells (4), we first examined two apoptosis hallmarks, PARP cleavage and caspase-3 processing (27) . Exponentially grown cells were treated with either the solvent or Alternol for up 
Then, we further confirmed Alternol-induced apoptosis by assessing DNA fragmentation. As shown in Fig 2B lower panel, in parallel to Alternol-induced caspase-3 processing and PARP cleavage, a typical DNA fragmentation was observed in a time-dependent manner after Alternol treatment. Next, we assessed the integrity of cellular plasma membrane and the exposure of inner phosphatigylserine by a combinational assay of propidium iodide (PI) staining and Annexin V binding. As shown in Fig 2C and 2D , Alternol treatment induced a significant increase of PI/Annexin V-dual positive population in PC-3 cells in a time-dependent manner but not in DU145 and BPH1 cells. In addition, a less than 10% of PC-3 or BPH1 cells were seen with PI staining, indicating a small portion of cells underwent necrotic cell death. We also investigated if caspases-9, the major component of apoptosome for apoptosis execution (28), was activated after Alternol treatment. As shown in Fig 2E, after Alternol treatment caspases-9 activity was significantly increased at 8-16 h post-treatment.
Mitochondria damage is often reported in chemodrug-induced apoptosis (29) . Therefore, we investigated whether Alternol treatment could cause any mitochondrial damage. We assessed the integrity of mitochondrial membrane permeability with a fluorescent dye JC-1, which exerts an orange color in healthy mitochondria but a green color when mitochondria are damaged (30) .
The results shown in Fig 2F and 2G revealed that in the majority of PC-3 cells compared to the solvent control, Alternol-treated cells appeared as green color, which was a clear sign of mitochondrial membrane potential transition (MPT) (31) . Taken together, these data demonstrated that Alternol mainly induced apoptotic cell death in prostate cancer cells.
Oxidative stress is essential in Alternol-induced apoptosis
Although a previous report showed Alternol-induced ROS response in mouse leukemia cells, the ROS involvement in cell death was not defined (3). We then went on to investigate if Alternol-induced oxidative stress and what was the significance in prostate cancer cell death. As shown in Fig 3A, when assessed with a total ROS detection assay Alternol treatment induced a dramatic oxidative response in a time-dependent manner. Quantitative analysis revealed that the oxidative stress was gradually increased after Alternol addition, which reached a significant level at 2-4 h post-treatment (Fig 3B) . Interestingly, Alternol treatment also induced a significant increase of ROS accumulation in DU145 cells but not in non-malignant BPH1 cells (Fig 3C), indicating that cancer cells are sensitive to ROS insults compared to non-malignant cells.
Next, we determined if oxidative stress was involved in Alternol-induced apoptotic cell death.
Two structurally distinct anti-oxidant compounds, N-acetylcysteine (N-Ac) and dihydrolipoic acid (DHLA) that can broadly scavenge ROS species were used to reduce ROS-induced cellular stress. As shown in Fig 3D, pre-treatment of the cells with these two compounds abolished Alternol-induced ROS accumulation. Most importantly, when cell death rate was assessed, pretreatment with N-Ac and DHLA significantly reduced Alternol-induced cell death (Fig 4A) .
Further analysis revealed that these two ROS scavengers abolished mitochondrial damage as assessed by JC-1 staining (Fig 2F & 2G) , PARP cleavage and caspase-3 processing (Fig 4B &   4C) . Alternol-induced casapse-9 activation (Fig 2E) and DNA fragmentation ( Fig 4D) were attenuated by N-Ac pre-treatment. These data suggest that oxidative response plays an essential role in Alternol-induced apoptosis.
Oxidative stress leads to Bax activation after Alternol treatment.
Bcl-2 family proteins including anti-apoptotic and pro-apoptotic members are major modulators of apoptosis (16) . Alternol was shown to down-regulate anti-apoptotic protein Bcl-2 and Bcl-x L expression in mouse leukemia cells (5) . In this study, we assessed the major members of Bcl-2 family proteins during Alternol treatment. Our results (Fig 5A) revealed that in addition to a dramatic decline of Bcl-2 protein level, a moderate increase of Bif-1 protein and a slight reduction of Bcl-x L protein expression, Alternol treatment induced a clear cleavage of Bax protein, a sign of Bax activation (32) . Most significantly, DU145 cell line that is lack of Bax expression (33) was sensitive to Alternol-induced ROS accumulation (Fig 3C) but resistant to Alternol-induced cell death (Fig 1C & 2A) , indicating a potential role of Bax activation in ROSdependent apoptosis after Alternol treatment. Then, we determined if the lack of apoptotic response in DU145 cells after Alternol treatment is due to Bax-null status. In contrast to Alternol, topoisomerase I inhibitor CPT-11 (35) that induces intrinsic apoptosis by causing DNA damage, induced a drastic response of caspase-3 processing and PARP cleavage in DU145 cells (Fig 5D) , indicating the apoptotic machinery is functional. Then, we restored Bax expression in DU145 cells, followed by Alternol treatment. As shown in Fig 5E, 
Since ROS scavengers N-Ac and DHLA abolished Alternol-induced apoptosis, and it has been reported that oxidative stress caused Bax activation (18, 20) , we examined if Alternolinduced Bax cleavage was due to oxidative stress. PC-3 cells were pretreated with N-Ac or DHLA before Alternol addition and Bax cleavage was evaluated by western blot assays. As shown in Fig 6A & 6B, either N Lastly, we determined if Alternol-induced Bax cleavage is dependent on calpain, which was shown to be involved in Bax cleavage/activation in chemotherapeutic drug-induced apoptosis (32, 36) . A broad spectrum inhibitor of cysteine proteases including calpain E-64 (37), a calpainspecific inhibitor PD150606 (38) and a dual calpain/proteasome inhibitor MG-132 (39) were used in PC-3 cells as a pre-treatment before Alternol addition. Compared to the solvent control, these inhibitors had no obvious inhibitory effect on Alternol-induced Bax cleavage, caspase-3 processing and PARP cleavage (Fig 6C) . These data demonstrated that Alternol-induced ROSdependent Bax activation and apoptotic cell death might be a calpain-independent mechanism. Tumor wet weights were also significantly lower in Alternol group than that in control group.
Alternol suppressed xenograft tumor growth in vivo
However, there was no significant difference in tumor growth rate in DU145 xenografts between Alternol group and the control group. Further analysis on paraffin-embedded xenograft tissue sections (Fig 7C & 7D) revealed that there was a significant increase of TUNEL-positive cells and the expression of cleaved caspase-3 in PC-3-derived xenografts after Alternol treatment compared to the control solvent. However, DU145-derived xenografts showed no obvious difference in either TUNEL index or cleaved caspase-3 expression between Alternol-treated and the solvent control. These data suggest that Alternol treatment suppressed tumor growth through Bax-dependent apoptosis in vivo.
Discussion
Here we reported the natural compound Alternol for its apoptosis-inducing effect on human prostate cancer cells, which is the first step towards new drug development for advanced prostate cancers. This apoptotic effect was achieved through a dramatic accumulation intracellular ROS species, resulting in a strong death response in either AR-positive or AR-negative prostate cancer cells regardless of their hormone responsiveness. In addition, we confirmed the Alternol preference in killing malignant over non-malignant cells through an oxidative stress-mediated Bax activation-dependent apoptotic pathway in vitro and in vivo. Consistently, Bax-null prostate cancer DU145 cells were resistant to Alternol-induced apoptotic cell death in vitro and in vivo.
These data provide a strong proof-of-principle that Alternol is feasible to be further developed as Oxidative stress is often induced by chemotherapeutic drugs in cancer cells (12) . Meanwhile, compared to non-malignant cells, malignant cells are much more vulnerable to oxidative stressinduced cell death due to elevated production of endogenous ROS (11, 40, 41) . Thus far, several cancer-specific ROS inducers were reported with promising results (42) (43) (44) . Although Alternol was previously reported to induce ROS accumulation in gastric cancer cells, its functional significance on cell death was not determined (3) . In this study, we demonstrated that oxidative stress was gradually accumulated after Alternol treatment. Furthermore, two structurally distinct anti-oxidants N-Ac and DHLA abolished Alternol-induced oxidative stress and apoptotic cell death, as evidenced by the completed blockage of caspases-3 processing, PARP cleavage, mitochondrial damage and DNA fragmentation. These data confirm the functional significance of ROS accumulation in Alternol-induced cytotoxicity.
Bcl-2 family proteins are the major regulators of apoptotic cell death, of which the proapoptotic Bax protein is the dominant one in triggering apoptosis (13) . Bax activation is a highly regulated multistep process, involving its conformational change and then translocation from the cytosol to the mitochondrial outer membrane where it is cleaved and oligomerizes (16, 45) . In this study, we presented another important finding that Bax protein was cleaved after Alternol treatment in parallel to intracellular ROS accumulation and subsequent apoptotic cell death. We demonstrated that Bax cleavage is functionally significant because the anti-oxidant agents completely blocked Bax cleavage and cell death. In addition, suppression of Bax function by either Bax channel blocker or Bax-specific siRNA attenuated Alternol-induced apoptosis. vivo. Nonetheless, Alternol-induced Bax cleavage was not suppressed by calpain inhibitors, although calpain was shown to mediate chemodrug-induced Bax cleavage (32, 36, 46, 47) , suggesting a calpain-independent mechanism. Although oxidative stress has been linked to Bax dimerization and activation (18, 20) , as we showed in this study, the exact mechanism for Alternol-induced Bax cleavage is still under further investigation by our group.
In this study, we found that the protein levels of anti-apoptotic Bcl-2 but not Bcl-X L significantly decreased while the Bax interacting protein Bif-1 moderately increased after Alternol treatment, which is supported by a previous report (5) . As a major Bax inhibitory protein, Bcl-2 down-regulation is postulated to facilitate Bax-mediated apoptotic cell death after Alternol treatment. Similar is true for Bif-1 that has been shown to enhance Bax function (48) (49) (50) .
However, the mechanisms underlying the expression changes of these Bcl-2 family proteins after Alternol treatment needs further investigation.
Finally, we conducted a pilot "proof-of-principle" experiment to assess the in vivo efficiency of Alternol on tumor inhibition. The growth rate of xenografts in nude mice derived from PC-3 but not DU145 showed a significant reduction in Alternol-treated animals compared to the solvent control. Analysis of the tissue section revealed that Alternol treatment induced a dramatic apoptotic response in PC-3 but not DU145-derived xenografts. These results were in line with a previous patent publication (US20090203775A1), showing in vivo anti-cancer effect of Alternol on human gastric cancer cell-derived xenografts. Our xenograft data also were consistent with cell culture data that DU145 cells were resistant to Alternol treatment due to Bax-null status. In spite that only one dose was implicated in our animal experiment, it is suggestive that Alternol possess a great potential as a novel small molecule anti-cancer agent for further pre-clinical and clinical development. In conclusion, we provided convincing evidences that natural compound Alternol is capable of inducing apoptotic cell death in prostate cancer cells through an oxidative stress-dependent Bax activation mechanism, which provides a proof-of-principle for further development as a novel anti-cancer drug for advanced prostate cancers. Future studies will elucidate the detailed mechanisms responsible for Alternol-induced intracellular ROS accumulation and changes in Bcl-2 family proteins, especially Bax cleavage and activation. 
